iCAD (NASDAQ:ICAD) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Shares of iCAD, Inc. (NASDAQ:ICAD) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.61 and traded as high as $2.06. iCAD shares last traded at $1.96, with a volume of 197,827 shares traded.

Analyst Ratings Changes

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st.

iCAD Price Performance

The stock has a market capitalization of $50.43 million, a price-to-earnings ratio of -14.62 and a beta of 1.40. The stock has a 50 day moving average price of $1.83 and a 200-day moving average price of $1.61.

Institutional Investors Weigh In On iCAD

An institutional investor recently bought a new position in iCAD stock. Essex LLC acquired a new stake in shares of iCAD, Inc. (NASDAQ:ICAD) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned approximately 0.52% of iCAD at the end of the most recent quarter. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.